Taipei Medical University

National Health Research Institutes

Calgent Biotechnology Co., Ltd.

National Taiwan University

The Ohio State University

Dcb-usa LLC

Cathay General Hospital

Jing-Ping Liou

Yun Yen

Jang-Yang Chang

Shiow-Lin Pan

Che-Ming Teng

Hsing-Pang Hsieh

Chun-Wei Chang

Kuo-Sheng Hung

Chien Huang Lin

Pei-Wen Shan

Ching-Shih Chen

Wen-Ta Chiu

Hsing-Jin Liu

Yu-Sheng Chao

Yi-Jen Chen

Chih-Cheng Chien

Cheng-Ying Hsieh

Chun-Han Chen

Yu-Hsun Kao

Yun-Ru Liu

Yen-Shih Tung

Chia-Ron Yang

Chao-Chien Chang

Chih-Ming Ho

Jia-Yi Wang

Fa-Kung Lee

Joen-Rong Sheu

Chun-Wei 4 Fl No 19 Chang

The invention relates to the use of a compound of Formula (I) as described herein and its effective dose in the prevention and/or treatment of fibrosis diseases. The compound can effectively prevent and/or treat a fibrosis disease without cytotoxicity or genotoxicity.

Aminonaphthoquinone compounds for treatment and/or prevention of fibrosis diseases

The invention relates to compounds of formula (I) with low cytotoxicity for blocking the ubiquitination-proteasome system in diseases. Accordingly, these compounds can be used in treatment of disorders including, but not limited to, cancers.

Aminonapthoquinone compounds and pharmaceutical composition for blocking ubiquitination-proteasome system in diseases

The invention provides a soluble honokiol derivative (such as a water soluble honokiol derivative) and its application in antagonizing glycoprotein VI receptor and providing antioxidant and neuroprotective effects.

Soluble honokiol derivatives

This disclosure is related to aromatic compounds of formula (I), and methods of their use in treating medical conditions associated with Heat Shock Protein-90 (HSP90), e.g., cancer. Compounds of formula (I) have the following structure: Also disclosed are pharmaceutical compositions comprising compounds of formula (I).

Heat shock protein 90 inhibitors

Disclosed is hydroxamic acid compounds of Formula (I) set forth herein. Also disclosed are a pharmaceutical composition containing such a compound and a method of using the compound for treating a condition associated with histone deacetylase 6.

Histone deacetylase 6 inhibitors and use thereof

The invention relates to the use of Indoline derivatives, and their effective dose in the prevention and/or treatment of fibrosis diseases. The compound can effectively prevent and/or treat a fibrosis disease without cytotoxicity or genotoxicity.

Indoline derivatives for treatment and/or prevention of fibrosis diseases

The invention relates to new compounds with low cytotoxicity for blocking ubiquitination-proteasome system in diseases. Accordingly, these compounds can be used in treatment of treating disorders including, but not limited to, cancers, neurodegenerative diseases, inflammatory disorders and autoimmune disorders and metabolic disorders.

Compounds and pharmaceutical composition associated with ubiquitination-proteasome system

The invention relates to compounds for inhibiting a cancer cell or a virus. Particularly, the invention provides compounds for inhibiting, treating and/or preventing cancer and Zika virus.

Compounds for inhibiting cancer and virus

The invention provides a series of chlorobenzene substituted azaaryl compounds having activity in inhibiting cancer cell growth and low toxicity to normal cells. Particularly, the compounds of the invention have stronger inhibition effect on bladder cancer and liver cancer.

Chlorobenzene substituted azaaryl compounds

The invention relates to a compound of formula (I) with low cytotoxicity for blocking the ubiquitination-proteasome system in diseases. Accordingly, these compounds can be used in treatment of disorders including, but not limited to, multiple myeloma, cancers, neurodegenerative diseases, inflammatory disorders, autoimmune disorders and metabolic disorders.

Fused bicycle indol, indoline, azoindole, or azoindoline compounds of Formula (I) set forth herein. Also disclosed are pharmaceutically acceptable salts of these compounds and pharmaceutical compositions containing the same. Further disclosed is a method for treating cancer, e.g., glioma, prostate cancer, and colorectal cancer, with these compounds.

Histone deacetylase inhibitors

Indolyl or indolinyl compounds of formula (I): whereinbond, n, R, R, R, R, R, and R, are defined herein. Also disclosed is a method for treating cancer with these compounds.

Indolyl or indolinyl hydroxamate compounds

Novel use of small molecules, particularly indolyl and indolinyl hydroxamates is disclosed herein. The indolyl and indolinyl hydroxamates are useful as lead compounds for manufacturing a medicament or a pharmaceutical composition for treating a patient suffering from heart failure or neuronal injury.

Growing community of inventors

Taipei, Taiwan

Jing-Ping Liou